Despite RemeGen's subdued revenue growth projections, it trades at a P/S ratio similar to the industry, suggesting investors may be less bearish than analysts. However, its weaker revenue outlook could risk a share price decline and pose a risk to shareholders.
荣昌生物股票讨论区
药品被出售。 $荣昌生物 (09995.HK)$ 一度下跌27.5%,至22.8美元;最后跌至24.9美元,下跌21%。
$三叶草生物-B (02197.HK)$ 暴跌9.6%,至0.47美元,创历史新低。 $维亚生物 (01873.HK)$ ...
这则消息引发了香港的抛售潮。
$药明生物 (02269.HK)$ $药明康德 (02359.HK)$ $三叶草生物-B (02197.HK)$ $荣昌生物 (09995.HK)$
暂无评论